Patient took the first dose was on Feb 16th 2 weeks prior to second dose; Wobbly; Shaking; Nervousness; Chills; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose), BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 013A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose). 02-Mar-2021, the patient experienced BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills). On 02-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose) had resolved. At the time of the report, BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Follow-up information received and does not contains any new information. This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 09-Mar-2021. The most recent information was received on 18-Jun-2021 and was forwarded to Moderna on 18-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose), BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 013A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose). 02-Mar-2021, the patient experienced BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills). On 02-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient took the first dose was on Feb 16th 2 weeks prior to second dose) had resolved. At the time of the report, BALANCE DISORDER (Wobbly), TREMOR (Shaking), NERVOUSNESS (Nervousness) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Follow-up information received and does not contains any new information.